Liposomal hydrogel formulation for transdermal delivery of pirfenidone

References

• Alexander A, Dwivedi S, Giri TK, et al. (2012). Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release 164:26–40
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–48
   PubMed Web of Science ®Google Scholar
• Arai T, Inoue Y, Sasaki Y, et al. (2014). Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 52:136–43
   PubMedGoogle Scholar
• Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–52
   PubMed Web of Science ®Google Scholar
• Barragán JM, Rodríguez AS, Partida JN, Borunda JA. (2010). The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 3:1–11
   PubMedGoogle Scholar
• Bouwstra JA, Ponec M. (2006). The skin barrier in healthy and diseased state. Biochim Biophys Acta 1758:2080–95
   PubMed Web of Science ®Google Scholar
• Bruss ML, Margolin SB, Giri N. (2004). Pharmacokinetics of orally administered pirfenidone in male and female Beagles. J Vet Pharmacol Therap 27:361–7
   PubMed Web of Science ®Google Scholar
• Cevc G, Blume G. (1992). Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1104:226–32
   PubMed Web of Science ®Google Scholar
• Cevc G, Blume G. (2004). Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 1663:61–73
   PubMed Web of Science ®Google Scholar
• Chen Y, Quan P, Liu X, et al. (2014). Novel chemical permeation enhancers for transdermal drug delivery. Asian J Pharm Sci 9:51–64
   Google Scholar
• Cho ME, Kopp JB. (2010). Pirfenidone: an anti-fibrotic and cytoprotective agent as therapy for progressive kidney disease. Expert Opin Investig Drugs 19:275–83
   PubMed Web of Science ®Google Scholar
• Costa AP, Xu X, Burgess DJ. (2014). Freeze-anneal-thaw cycling of unilamellar liposomes: effect on encapsulation efficiency. Pharm Res 31:97–103
   PubMed Web of Science ®Google Scholar
• Cottin V. (2013). The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 14:1–4
   PubMed Web of Science ®Google Scholar
• Duck A, Pigram L, Errhalt P, et al. (2015). IPF care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Adv Ther. 32:87–107
   PubMed Web of Science ®Google Scholar
• El-nabarawi MA, Bendas ER, Rehem RT, Abary MYS. (2013). Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. Int J Pharm 443:307–17
   PubMed Web of Science ®Google Scholar
• Fyfe CA, Blazek AI. (1997). Investigation of hydrogel formation from hydroxypropyl methylcellulose (HPMC) by NMR spectroscopy and NMR imaging techniques. Macromolecules 30:6230–7
   Web of Science ®Google Scholar
• Hope MJ, Bally MB, Mayer LD, et al. (1986). Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 40:89–107
   Web of Science ®Google Scholar
• Jung KI, Choi JS, Kim HK, Shin SY. (2012). Effects of an anti-transforming growth factor-β agent (pirfenidone) on strabismus surgery in rabbits. Curr Eye Res 37:770–6
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–92
   PubMed Web of Science ®Google Scholar
• Larrucea E, Arellano A, Santoyo S, Ygartua P. (2001). Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm 52:113–19
   PubMed Web of Science ®Google Scholar
• Lasic DD, Ceh B, Stuart MCA, et al. (1995). Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1239:145–56
   PubMed Web of Science ®Google Scholar
• Liu D, Mori A, Huang L. (1992). Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1104:95–101
   PubMed Web of Science ®Google Scholar
• Lou Q, Meng X, Lao Z, et al. (2012). Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones. Molecules 17:884–96
   PubMed Web of Science ®Google Scholar
• Maghraby GMME, Williams AC, Barry BW. (2006). Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol 58:415–29
   PubMed Web of Science ®Google Scholar
• Moghadam SH, Saliaj E, Wettig SD, et al. (2013). Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm 10:2248–60
   PubMed Web of Science ®Google Scholar
• Moreira TS, de Sousa VP, Pierre MBR. (2010). A novel transdermal delivery system for the anti-inflammatory lumiracoxib: influence of oleic acid on in vitro percutaneous absorption and in vivo potential cutaneous irritation. AAPS Pharm Sci Tech 11:621–9
   PubMed Web of Science ®Google Scholar
• Peppas NA, Bures P, Leobandung W, Ichikawa H. (2000). Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 50:27–46
   PubMed Web of Science ®Google Scholar
• Taylor DK, Leppert PC. (2012). Treatment for uterine fibroids: searching for effective drug therapies. Drug Discov Today Ther Strateg 9:e41–9
   PubMedGoogle Scholar
• Togami K, Miyao A, Miyakoshi K, et al. (2015). Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis. Biol Pharm Bull 38:270–6
   PubMed Web of Science ®Google Scholar
• Venuganti VV, Perumal OP. (2009). Nanosystems for dermal and transdermal drug delivery. Drug delivery nanoparticles formulation and characterization. New York: Informa Healthcare Inc
   Google Scholar
• Xu X, Khan MA, Burgess DJ. (2012). Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm 423:410–18
   PubMed Web of Science ®Google Scholar